Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients

INTRODUCTION: Glycoprotein IIb/IIIa inhibitors are recommended by guidelines in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. There are few studies directly comparing these agents. The aim of this study was to assess whether eptifib...

Descripción completa

Detalles Bibliográficos
Autores principales: Rathod, KS, Antoniou, S, Avari, P, Ding, N, Wright, P, Knight, C, Jain, AK, Mathur, A, Smith, EJ, Weerackody, R, Wragg, A, Jones, DA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637964/
https://www.ncbi.nlm.nih.gov/pubmed/29051816
http://dx.doi.org/10.1177/2048004017734431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637964/
https://www.ncbi.nlm.nih.gov/pubmed/29051816
http://dx.doi.org/10.1177/2048004017734431

Ejemplares similares